VERA News and Press, Vera Therapeutics Inc. From 04/18/23

2023-04-18 00:41:35 ET Summary Shares of immunological disorder concern Vera Therapeutics, Inc. cratered 75% in early January despite its immunoglobulin A nephropathy candidate achieving its primary endpoint. The data were not overwhelming but certainly enough to advance atacicept...

2023-03-28 07:54:10 ET Vera Therapeutics press release ( NASDAQ: VERA ): FY GAAP EPS of -$3.35 misses by $0.34 . Vera reported $114.7 million in cash, cash equivalents, and marketable securities as of December 31, 2022. Subsequent to December 31, 2022, the company rais...

Announced positive interim data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which showed a 41% mean reduction in proteinuria versus baseline in the 150mg dose group at 24 weeks 36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN on track for the...

BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management...

Summary Chinook is a clinical-stage biopharmaceutical firm that is developing precision medicines for kidney diseases, including treatments for rare, chronic, and severe kidney conditions. Its lead program, atrasentan, is a potent antagonist of the endothelin A receptor undergoing a pha...

BRISBANE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the closing ...

Vera Therapeutics ( NASDAQ: VERA ) prices its underwritten public offering of 14.29M shares at a price to the public of $7.00 per share. The gross proceeds are expected to be $100M. Underwriters have 30-day option to purchase up to an additional ~2.14M shares. The offe...

BRISBANE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc., (NasdaqGM: VERA; “Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing...

Vera Therapeutics ( NASDAQ: VERA ), a clinical-stage biotech focused on immunological diseases lost ~7% in the post-market trading Wednesday after announcing a public offering to issue and sell 75M shares of its Class A common stock. A decision to grant a 30-day option for underwr...

Summary Vera Therapeutics has released an updated interim PP analysis on the phase 2b ORIGIN trial. The updated data excluded 14 patients who had some degree of a trial protocol violation, further enriching the data. The PP data was better than ITT data, where 36 weeks of data of th...